Group 1 - Company Wuchan Jinyun plans to reduce its shareholding by up to 3%, amounting to a maximum of 6.24 million shares [1] - Company Hualing Steel's shareholder intends to increase its stake by 1% to 2%, acquiring between 6.91 million and 13.8 million shares [1] - Company Zhujiang Co. plans to sell multiple stock assets, potentially generating over 50% of its audited net profit from the previous year [1] Group 2 - Company Dash Smart's actual controller plans to reduce holdings by up to 1.52%, equating to 30.41 million shares [2] - Company Zhendian Medical's controlling shareholder intends to transfer 5% of its shares, totaling 13.32 million shares, at a price of 26.74 yuan per share [2] - Company Dajin Heavy Industry's subsidiary signed a contract worth approximately 1.25 billion yuan for offshore wind power foundations, representing about 33% of its projected revenue for 2024 [4] Group 3 - Company Andy Su received approval for a stock issuance to specific investors [5] - Company Shield Environment plans to invest approximately 5 billion yuan in a new smart manufacturing headquarters project [7] - Company Dongfang Guoxin intends to establish a joint venture with Shunyi Jin Kong with a registered capital of 300 million yuan [8] Group 4 - Company ST Lian Shi signed a pre-restructuring investment agreement with selected investors, with share prices set at 5.65 yuan and 6.73 yuan for different lock-up periods [9][10] - Company Langzi Co. plans to acquire 67.5% of Chongqing Time for 92.475 million yuan [11] - Company Yingli Co. intends to purchase 77.94% of Youte Li for 468 million yuan and raise up to 196 million yuan through a private placement [13] Group 5 - Company Betta Pharmaceuticals plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [14] - Company Hehua Co. intends to transfer control by selling 23.76% of its shares for 632 million yuan [16] - Company Jieshun Technology's shareholder plans to reduce holdings by up to 3%, totaling 1.92 million shares [18] Group 6 - Company Wuyang Zikong's controlling shareholder plans to transfer 15% of its shares, changing the controlling party [19] - Company Zhongliang Kegong plans to reduce its shareholding by up to 3%, amounting to 1.54 million shares [20] - Company Changhua Chemical intends to reduce its shareholding by up to 3%, totaling 417,420 shares [22]

Core Viewpoint - The company plans to utilize the net proceeds from fundraising for functional product projects, specialty product projects, sustainable development projects, and to supplement working capital [1] Group 1: Fundraising Utilization - The net proceeds will be allocated to a 150,000 tons/year solid methionine project, a 37,000 tons/year specialty feed additive project, and a wastewater treatment and water reuse project [1] - The solid methionine project aims to expand China's methionine production capacity and optimize product structure and capacity layout [1] - The specialty product projects focus on cost reduction and capacity expansion, positioning specialty products as the second major revenue driver [1] Group 2: Sustainable Development - The sustainable development projects aim to reduce pollutants and lower carbon emissions, contributing to energy conservation and emission reduction goals [1] Group 3: Financial Strength and Strategic Outlook - The fundraising will enhance the company's capital strength, optimize the asset-liability structure, alleviate operational cash flow pressure, and reduce financial risks [1] - Strengthened financial capabilities will support the company's optimization in industry chain layout, new business development, and technological innovation [1] Group 4: Company Overview - The company, Andisu, is a global leader in animal nutrition additives, focusing on the research, production, and sales of these additives [1] - The company's stock closed at 9.79 yuan per share on September 10 [1]

（文章来源：证券日报） 证券日报网讯 9月10日晚间，安迪苏发布公告称，公司于2025年9月9日收到上海证券交易所出具的《关 于同意蓝星安迪苏股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕1970号），主要 内容如下："一、同意你公司向特定对象发行股票的注册申请。二、你公司本次发行应严格按照报送上 海证券交易所的申报文件和发行方案实施。三、本批复自同意注册之日起12个月内有效。四、自同意注 册之日起至本次发行结束前，你公司如发生重大事项，应及时报告上海证券交易所并按有关规定处 理。" ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-043 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方案实施。 三、本批复自同意注册之日起 12 个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及时报告 上海证券交易所并按有关规定处理。" 公司董事会将根据上述批复文件和相关法律、法规的要求及公司股东会的授权， 在规定期限内办理本次向特定对象发行股票相关事宜，并及时履行信息披露义务。敬 请广大投资者注意投资风险。 特此公告。 蓝星安迪苏股份有限公司董事会 关于向特定对象发行股票申请获得中国证券监督管理委员 会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日收到上海证券交 易所（以下简称"上交所"）出具的《关于同意蓝星安迪苏股份有限公司向特定对象发 行股票注册的批复》（ 证监许可〔2025〕1970 号），主要内容如下： "一、同意你公司向特定对象发行股票的注册申请。 蓝星安迪苏 ...

人民财讯9月10日电，安迪苏（600299）9月10日晚间公告，公司9月9日收到上海证券交易所出具的《关 于同意蓝星安迪苏股份有限公司向特定对象发行股票注册的批复。同意公司向特定对象发行股票的注册 申请。 ...

安迪苏公告，公司于2025年9月9日收到上交所出具的《关于同意蓝星安迪苏股份有限公司向特定对象发 行股票注册的批复》（证监许可〔2025〕1970号）。主要内容包括：同意公司向特定对象发行股票的注 册申请；本次发行应严格按照报送申报文件和发行方案实施；本批复自同意注册之日起12个月内有效。 公司将根据批复文件和相关法律、法规要求，在规定期限内办理本次发行相关事宜，并及时履行信息披 露义务。 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-042 蓝星安迪苏股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第三次临时股东大会 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等有关 规定执行。 (七)涉及公开征集股东投票权 (二)股东大会召集人：董事会 召开的日期时间：2025 年 9 月 25 日 14 点 00 分 召开地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 (五)网 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company [2][5]. Core Insights - The company reported a robust performance in the first half of 2025, achieving a revenue of 8.512 billion yuan, representing a year-over-year increase of 17.23%, and a net profit of 740 million yuan, up 21.82% year-over-year [3]. - The core business segments showed steady growth, with the functional products segment revenue increasing by 20% to 6.47 billion yuan, driven by the growth in methionine sales and an increase in market penetration of liquid methionine [3]. - The special products segment also saw a revenue increase of 9% to 2.04 billion yuan, attributed to strong sales growth in ruminant products outside of China and a rebound in aquatic product sales [3]. - The company is enhancing its methionine production capacity, with ongoing projects in Europe and China, including a new solid methionine plant in Quanzhou expected to be operational by 2027 [4]. Financial Performance Summary - The company’s EBITDA margin improved to 22% in the first half of 2025, benefiting from cost control and operational efficiency initiatives [3]. - The financial forecast for 2025-2027 estimates net profits of 1.637 billion, 1.852 billion, and 2.025 billion yuan, with corresponding EPS of 0.61, 0.69, and 0.75 yuan [5]. - The projected revenue for 2025 is 17.939 billion yuan, with a growth rate of 15.48% [6]. Company Overview - The company is recognized as the second-largest methionine producer globally, capable of producing both solid and liquid methionine, and is a leader in the animal nutrition and health industry [7].

Group 1 - The core viewpoint of the articles highlights the strong performance of Andisu in the first half of 2025, with a 17% year-on-year increase in revenue to 8.51 billion yuan and a 22% increase in net profit attributable to shareholders to 740 million yuan [1][2] - The sales of methionine business grew by 16% year-on-year, driven by the increasing market penetration of liquid methionine, despite challenges from regional price declines and rising raw material costs [1][2] - The special products business saw a 9% increase in revenue to 2.04 billion yuan and a 7% increase in gross profit to 830 million yuan, attributed to strong sales growth in ruminant products and a rebound in aquatic product sales [1][2] Group 2 - The "China Integration Strategy" has successfully driven strong sales growth in the first half of 2025, with double-digit growth in liquid methionine and significant orders in the aquatic market [2] - Andisu announced a refinancing plan to raise no more than 3 billion yuan to support investment projects, which has been approved by the Shanghai Stock Exchange and is currently in the registration process with the China Securities Regulatory Commission [2] - The company implemented a mid-term and annual dividend plan with an overall payout ratio of 40.08%, distributing 161 million yuan as mid-term dividends and 322 million yuan as annual dividends to shareholders [2]

Market Performance - The chemical products sector increased by 0.37% on September 1, with *ST Jintai leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chemical Sector - *ST Quantai (300225) closed at 5.79, up 12.21% with a trading volume of 366,800 shares and a turnover of 204 million yuan [1] - Kangda New Materials (002669) closed at 15.46, up 10.04% with a trading volume of 305,700 shares [1] - Jianye Co. (603948) closed at 32.09, up 10.01% with a trading volume of 25,800 shares [1] - Dinglong Technology (603004) closed at 24.42, up 10.00% with a trading volume of 78,100 shares [1] - Zanyu Technology (002637) closed at 12.02, up 9.97% with a trading volume of 154,400 shares [1] Top Losers in Chemical Sector - Akole (603722) closed at 51.95, down 7.99% with a trading volume of 75,000 shares and a turnover of 392 million yuan [2] - Jiabiyou (688089) closed at 27.36, down 5.07% with a trading volume of 122,100 shares [2] - Andyshi (66ZOO9) closed at 10.07, down 4.82% with a trading volume of 271,400 shares [2] Capital Flow Analysis - The chemical products sector experienced a net outflow of 361 million yuan from institutional investors, while retail investors saw a net inflow of 243 million yuan [2][3] - Kangda New Materials (002669) had a net inflow of 1.21 billion yuan from institutional investors, but a net outflow of 55.12 million yuan from retail investors [3] - Zanyu Technology (002637) had a net inflow of 61.87 million yuan from institutional investors, with a net outflow of 32.00 million yuan from retail investors [3]